Kymera Investor Presentation Deck
Plasma KT-413 Concentration (ng/mL)
1000
100
10
O
Plasma PK Showing Dose-Proportional Increase in Exposure
4 8 12
Cycle 1 Plasma PK
24
Time (h)
KYMERA ©2023 KYMERA THERAPEUTICS, INC.
48
DL1: 0.16 mg/kg
DL2: 0.32 mg/kg
DL3: 0.51 mg/kg
DL4: 0.82 mg/kg
72
PK
Parameter
Cmax (ng/mL)
AUC inf
(ug.h/mL)
Vd (L/kg)
CL (L/h/kg)
t₁/2 (h)
Cycle 1 PK Parameters
DL2
DL1
DL3
0.16 mg/kg 0.32 mg/kg 0.51mg/kg
(n = 1)
(n = 1)
(n = 1)
140
1380
10.1
0.116
60.3
546
3750
4.51
0.0853
36.7
598
7580
5.41
0.0673
55.8
Individual values shown for DL1-DL3; Mean (individual values) shown for DL4 since data
from only 2 patients is available.
DL4
0.82mg/kg
(n = 2)
1500
(1140, 1850)
9340
(10800, 7860)
4.66
(3.92, 5.40)
0.0901
(0.0758, 00104)
35.9
As of the data cut-off date of June 1, 2023.
PAGE 38View entire presentation